Literature DB >> 19995680

Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

N A Mufti1, A C Erickson, A K North, D Hanson, L Sawyer, L M Corash, L Lin.   

Abstract

A pathogen inactivation (PI) process has been developed using the frangible anchor linker effector (FRALE) compound S-303. A series of experiments were performed in whole blood (WB) to measure the level of viral and bacterial inactivation. The results showed that 0.2mM S-303 and 2mM glutathione (GSH) inactivated >6.5 logs of HIV, >5.7 logs of Bluetongue virus, >7.0 logs of Yersinia enterocolitica, 4.2 logs of Serratia marcescens, and 7.5 logs of Staphylococcus epidermidis. Recent development for S-303 is focused on optimization of the PI process for red blood cell concentrates (RBC). A series of studies in RBC showed that 0.2mM S-303 and 20mM GSH inactivated approximately 5 logs or greater of Y. enterocolitica, E. coli, S. marcescens, S. aureus, HIV, bovine viral diarrhoea virus, bluetongue virus and human adenovirus 5. In both applications of the S-303 process, in vitro parameters of RBC function and physiology were retained compared to conventional RBC. Results from these studies indicate that S-303 can be applicable for PI of RBC and WB. Copyright 2009 The International Association for Biologicals. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995680     DOI: 10.1016/j.biologicals.2009.10.019

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  11 in total

Review 1.  Current testing strategies for hepatitis C virus infection in blood donors and the way forward.

Authors:  Neelam Marwaha; Suchet Sachdev
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates.

Authors:  Reinhard Henschler; Erhard Seifried; Nina Mufti
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

Review 3.  Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Authors:  Susan Yonemura; Suzann Doane; Shawn Keil; Raymond Goodrich; Heather Pidcoke; Marcia Cardoso
Journal:  Blood Transfus       Date:  2017-05-11       Impact factor: 3.443

Review 4.  Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

Authors:  Susanne M Picker
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

Review 5.  Pathogen inactivation technologies for cellular blood components: an update.

Authors:  Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2014-07-21       Impact factor: 3.747

6.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

7.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.

Authors:  Rachael P Jackman; Marcus O Muench; Heather Inglis; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2016-11-18       Impact factor: 3.157

Review 8.  Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion.

Authors:  Giona Sonego; Mélanie Abonnenc; Jean-Daniel Tissot; Michel Prudent; Niels Lion
Journal:  Int J Mol Sci       Date:  2017-02-11       Impact factor: 5.923

9.  Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).

Authors:  Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness
Journal:  Transfusion       Date:  2019-05-29       Impact factor: 3.157

Review 10.  [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].

Authors:  J-P Cazenave
Journal:  Transfus Clin Biol       Date:  2011-04-06       Impact factor: 1.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.